Driving the Development of Gene Therapies for Complement-Mediated Diseases to Deliver Sustained Patient Benefit

• Investigating gene therapy approaches capable of providing long-term complement control
• Navigating delivery, safety, and expression durability challenges to maximize therapeutic impact
• Translating learnings from the development pipeline into successful clinical and commercial outcomes

NEW SPEAKING COMPANY

Speakers:

Thomas Ciulla

Chief Executive Officer

Ikarovec